RxDoctor Payments DataLook up a doctor →

Manzar Rajput, MD

Psychiatry · Monroe, MINPI 1851358527

Payments from drug & device makers

$612,193in general payments, 2019–2025

Across 1,048 payments — averaging $584.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$201K
  • Axsome Therapeutics, Inc.$140K
  • Teva Pharmaceuticals USA, Inc.$123K
  • E.r. Squibb & Sons, L.L.C.$73K
  • Alkermes, Inc.$51K
  • Idorsia Pharmaceuticals US Inc$20K
  • plus $3K from 14 others

What the payments were for

  • Consulting fees$88,64614%
  • Speaking & faculty fees$469,68477%
  • Travel & lodging$29,7355%
  • Food & beverage$23,9174%
  • Education$2110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$612,193 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.

See all psychiatry providers in Michigan

Medicare billing

Part B allowed, 2024
$134,358
Medicare patients
231
Services billed
1,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate54$139,509
VraylarCariprazine Hcl84$117,795
LybalviOlanzapine/Samidorphan Malate63$102,062
AuvelityDextromethorphan Hbr/Bupropion70$77,365
UzedyRisperidone11$68,782
TrintellixVortioxetine Hydrobromide78$43,923
Abilify MaintenaAripiprazole12$34,923
ZyprexaOlanzapine14$28,422
ClozarilClozapine13$24,335
Clozapine164$13,139
VyvanseLisdexamfetamine Dimesylate21$8,640
Clozapine OdtClozapine13$8,165
Bupropion XlBupropion Hcl347$7,432
Chlorpromazine Hcl26$5,957
Depakote ErDivalproex Sodium14$5,600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$210$139,50954 claims
AbbVieVraylar$201,076$117,79584 claims
Alkermes, Inc.Lybalvi$51,158$102,06263 claims
Axsome Therapeutics, Inc.Auvelity$140,246$77,36570 claims
Teva Pharmaceuticals USA, Inc.Uzedy$123,434$68,78211 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$276$52,56399 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$1,204$34,92312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,166 psychiatry providers in Michigan.

Other psychiatry in Monroe

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →